5 Best Healthcare Stocks to Buy According to Billionaire Larry Robbins

4. Bausch Health Companies (NYSE:BHC)

Glenview Capital’s Stake Value: $211,515,000

Percentage of Glenview Capital’s 13F Portfolio: 4.28%

Number of Hedge Fund Holders: 48

As of this February, RBC Capital analyst Douglas Miehm has a $34 price target and Outperform rating on Bausch Health Companies (NYSE:BHC). Bausch Health Companies (NYSE:BHC) develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products for eye health, gastroenterology, and dermatology.

On May 10, Bausch Health Companies (NYSE:BHC) released earnings for the fiscal first quarter of 2022. The company registered an EPS of $0.72, missing estimates by $0.30. The company’s revenue for the quarter came in at $1.92 billion, down 5.38% year over year, and was short of expectations by $121.51 million.

As of March 31, Glenview Capital owns over 9.2 million shares of Bausch Health Companies (NYSE:BHC). The fund’s stakes are valued at $211.51 million, which covers 4.28% of its investment portfolio. Glenview Capital is among the top five shareholders in the company.

At the close of Q1 2022, 48 hedge funds were long Bausch Health Companies (NYSE:BHC) with stakes worth $3.17 billion in the company. This is compared to 53 positions in the previous quarter with stakes of $3.86 billion.